Summit Therapeutics SMMT Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's investment proceeds?
- Summit Therapeutics (SMMT) reported investment proceeds of $177.29M in Q1 2026.
- How has Summit Therapeutics's investment proceeds changed year-over-year?
- Summit Therapeutics's investment proceeds increased by 10.4% year-over-year, from $160.53M to $177.29M.
- What does investment proceeds mean?
- Cash received from selling investments or when investments reach their maturity date.
- How do you interpret investment proceeds?
- An increase indicates the company is liquidating investments to raise cash for operations or capital needs.
- How does investment proceeds compare across companies?
- Common for companies with significant cash balances; reflects treasury management strategies.